Medicenna Therapeutics Corp. (MDNA)
| Market Cap | 71.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.35M |
| Shares Out | 70.21M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | 208.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,618,841 |
| Open | 1.10 |
| Previous Close | 1.05 |
| Day's Range | 1.02 - 1.11 |
| 52-Week Range | 0.76 - 2.94 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 5.86 (+474.5%) |
| Earnings Date | Aug 15, 2022 |
About MDNA
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune ce... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MDNA stock is "Buy." The 12-month stock price forecast is 5.86, which is an increase of 474.51% from the latest price.
News
Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights
-- Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline
TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to announ...
Medicenna Announces Pricing of US$20 Million Public Offering of Units
TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today that...
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units
TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the ...
Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022
TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11's Single Agent Anti-Cancer Activity in...
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study's low and mid-stage dose escalation cohorts
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
--Cash runway extended late into calendar Q2 2023
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
TORONTO and HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that ...
Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022
TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontier...
-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity)
Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...
Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR ...
-- Anti-PD1-IL-2 BiSKIT ( Bi -functional S uper K ines for I mmuno T herapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition
Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the...
-- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor
Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting
TORONTO and HOUSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...
Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor
Medicenna's Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2
Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights
-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022
Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9...
TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee
Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in m...
Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA1...
-- Peak CD8 + T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial's first two dose escalation cohorts
Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada
-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States
Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th An...
TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced tha...
Medicenna Reports Second Quarter Fiscal 2022 Financial Results and Operational Highlights
-- Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022
Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference
-- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP)
Medicenna Appoints Dr. John H. Sampson to its Board of Directors
Announces Results of Annual Meeting of Shareholders Announces Results of Annual Meeting of Shareholders
Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit
TORONTO and HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced th...